Assay-Guided Therapy Improves Survival in High-Grade Glioma
Patients who received treatment selected by the ChemoID assay had superior progression-free survival and overall survival.
Incidence among children, adolescents increased 0.5 to 0.7 percent; malignant tumor incidence highest for males, non-Hispanic Whites